NCPA urges Pa. governor to approve state pharmacy bill
ALEXANDRIA, Va. — A group that lobbies on behalf of independent pharmacies is urging Pennsylvania Gov. Tom Corbett to sign a bill that would allow retail pharmacies to match the reimbursement terms, pricing and conditions that mail-order pharmacies negotiate exclusively with health insurance plans.
The National Community Pharmacists Association expressed hopes that Corbett would sign S.B. 201, which the Pennsylvania state Senate and House have unanimously approved.
“Quite simply, S.B. 201 is a significant step in the right direction for supporting local Pennsylvania jobs, increasing local tax revenue and providing citizens of Pennsylvania with the freedom of choice as to where they access their healthcare and medication needs, at absolutely no additional cost to the individual or healthcare system,” a letter from the NCPA to Corbett read.
The organization said there are 1,000 independent pharmacies in Pennsylvania that provide about 10,600 jobs, citing a Walgreens study conducted in April showing that 4-in-5 patients prefer community pharmacies over mail order, while a J.D. Power and Associates study indicates “growing dissatisfaction” with mail-order pharmacies despite many health plans requiring patients to use them. Most mail-order pharmacies are run by pharmacy benefit managers.
Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.
As a pharmacist in Florida I would sure like to see this happen in our (Florida) state.
FDA approves Eisai’s Fycompa for epilepsy
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for epilepsy, the agency said Monday.
The FDA announced the approval of Eisai’s Fycompa (perampanel) tablets to treat partial-onset seizures in patients ages 12 years and older. Partial seizures are the most common type seen in people with epilepsy, according to the FDA.
"Some people with epilepsy do not achieve satisfactory seizure control from treatments they are currently using," FDA Division of Neurology Products director Russell Katz said. "It is important to have a variety of treatment options available for patients with epilepsy."
No comments found
J&J drug appears more effective in ulcerative colitis patients than placebo, according to study
LAS VEGAS — More patients with an inflammatory disease of the bowels responded to a drug used for autoimmune disorders than those taking a placebo, according to results of a late-stage clinical trial announced Monday.
Johnson & Johnson said phase-3 trial findings showed that "significantly" more patients with severely active ulcerative colitis responded to Simponi (golimumab), maintaining their responsiveness to the drug through the 54th week. The drug is already approved by the Food and Drug Administration for treating conditions like rheumatoid arthritis.
The study program enrolled 1,228 patients who received induction therapy with injections of Simponi or placebo. The study indicated that 47% of patients receiving 50 mg of Simponi and 51% of those receiving 100 mg of the drug responded to therapy, compared with 31% of those receiving placebo.
No comments found